Vascular endothelial growth factor and its receptor, Flt-1, in smokers and nonsmokers

FM Belgore, GYH Lip, AD Blann - British journal of biomedical …, 2000 - search.proquest.com
FM Belgore, GYH Lip, AD Blann
British journal of biomedical science, 2000search.proquest.com
Raised levels of plasma vascular endothelial growth factor (VEGF) are found in some
cancers, diabetes, and certain other conditions, but levels of its receptor, soluble Flt-1 (sFlt-
1), in these diseases have yet to be reported. We hypothesised that smoking would
influence levels of these molecules. Consequently, we measured VEGF and sFlt-1 by
enzyme-linked immunosorbent assay (ELISA) in plasma from 92 non-smokers and 35
smokers. No difference in VEGF was seen between the groups but, despite considerable …
Abstract
Raised levels of plasma vascular endothelial growth factor (VEGF) are found in some cancers, diabetes, and certain other conditions, but levels of its receptor, soluble Flt-1 (sFlt-1), in these diseases have yet to be reported. We hypothesised that smoking would influence levels of these molecules. Consequently, we measured VEGF and sFlt-1 by enzyme-linked immunosorbent assay (ELISA) in plasma from 92 non-smokers and 35 smokers. No difference in VEGF was seen between the groups but, despite considerable overlap, sFlt-1 was significantly lower in smokers (P= 0.027). VEGF and sFlt-1 correlated strongly with each other (P< 0.001). Although VEGF may arise from a number of cell types, including endothelial cells, the primary source of sFlt-1 is thought to be the endothelium; however, neither VEGF nor sFlt-1 correlated with levels of the endothelial cell activation/damage marker soluble thrombomodulin. Our data point to changes in levels of the VEGF receptor, sFlt-1--but not VEGF itself--in smokers, which appears to be unrelated to endothelial cell function.
ProQuest